Expert Kept From Speaking at Antidepressant Hearing

[Guest guest]

April 16, 2004

Expert Kept From Speaking at Antidepressant Hearing

By GARDINER HARRIS

op Food and Drug Administration officials admitted yesterday that they barred

the agency's top expert from testifying at a public hearing about his conclusion

that antidepressants cause children to become suicidal because they viewed his

findings as alarmist and premature.

" It would have been entirely inappropriate to present as an F.D.A. conclusion an

analysis of data that were not ripe, " Dr. Temple, the Food and Drug

Administration's associate director of medical policy, said in an interview.

" This is a very serious matter. If you get it wrong and over-discourage the use

of these medicines, people could die. "

Dr. Temple was seeking to quell a growing controversy into whether the agency's

warnings on March 22 that antidepressant therapy could lead patients to become

suicidal were sufficient.

" There is concern that we hid data, " said Dr. Temple. " We did not hide data. It

was there for all to see. "

Recent studies have shown that children given antidepressants are more likely to

become suicidal than those given placebos. But the studies have lead to

different interpretations by psychiatrists. The refusal by drug companies to

publish the studies has worsened the confusion. Internal agency documents

obtained by The New York Times show that federal health officials are divided,

too.

Dr. D. Mosholder, an agency epidemiologist, was the man charged with

analyzing 22 studies involving 4,250 children and seven drugs. In a carefully

argued, 33-page memorandum, he concluded that children given antidepressants

were almost twice as likely as those given placebos to become suicidal.

He urged the agency to discourage doctors from prescribing to children all

antidepressants except Prozac. Prozac is the only antidepressant proven

effective in treating depressed children, and its studies showed no link with

suicide, Dr. Mosholder wrote. Dr. Mosholder's conclusions mirrored those made by

British health authorities.

But Dr. Mosholder's supervisors, Drs. Mark Avigan and Anne Trontell, wrote

memorandums disagreeing, according to the documents.

" In particular, we disagree that the data are sufficiently robust to advocate

preferential use " of Prozac in children, Dr. Trontell wrote.

Health officials convened a special advisory committee on Feb. 2 to offer

guidance on how the agency should respond to the studies. As the agency's

principal reviewer, Dr. Mosholder was scheduled to speak. He was removed from

the agenda, Dr. Temple said.

Senator E. Grassley, a Republican from Iowa and chairman of the Senate

Finance Committee, said he was investigating whether the agency inappropriately

suppressed crucial findings. Representative Joe L. Barton, a Republican from

Texas who is chairman of the House Energy and Commerce Committee, said he was

also investigating.

" It would have been very wrong for the F.D.A. to withhold any information it had

about unintended consequences that might result from the use of antidepressants,

especially for children and adolescents, " Mr. Grassley said.

Dr. Temple was unapologetic about the decision.He said that Dr. Mosholder's

underlying data were presented to the committee but that agency officials

explained that Dr. Mosholder had failed to treat with the appropriate skepticism

some reports of suicidal behavior.

The Food and Drug Administration has hired investigators at Columbia University

to examine reports from about 400 of the 4,250 children and determine

independently which should be classified as suicidal.

The controversy had its start when GlaxoKline sought a six-month extension

to its patents on Paxil. To help guide pediatricians' prescribing habits,

federal law grants such extensions when companies test their medicines in

children.

The company's studies in depressed children failed to show any positive effect.

It was a disappointing finding, but patent extensions are granted even when

studies fail. Reviewing the data, Dr. Mosholder noticed in October 2002 that

they showed a disturbing number of problems listed under the category,

" emotional liability. " Suicidal thoughts and self-injurious behavior were among

the things lumped into this category. Dr. Mosholder asked GlaxoKline to

provide more detail about these cases, according to one of the documents.

In May 2003, the company submitted a new report. It showed that children given

Paxil were more likely to become suicidal than those given placebos. In June,

the agency announced that doctors should avoid using Paxil in depressed

children.

Three days later, according to documents and interviews, the agency asked for

similar data from the makers of Prozac, Zoloft, Luvox, Celexa, Wellbutrin,

Effexor, Serzone and Remeron.

Dr. Mosholder found that 108 of the 4,250 children had done something that

merited being called suicidal. He divided the cases into those who were given

drugs and those given placebos and found that children given drugs were almost

twice as likely to become suicidal as those given placebo.

The agency declined to make Dr. Mosholder available for an interview.

Copyright 2004 The New York Times Company | Home | Privacy Policy | Search |

Corrections | Help | Back to Top

[Guest guest]

April 16, 2004

Expert Kept From Speaking at Antidepressant Hearing

By GARDINER HARRIS

op Food and Drug Administration officials admitted yesterday that they barred

the agency's top expert from testifying at a public hearing about his conclusion

that antidepressants cause children to become suicidal because they viewed his

findings as alarmist and premature.

" It would have been entirely inappropriate to present as an F.D.A. conclusion an

analysis of data that were not ripe, " Dr. Temple, the Food and Drug

Administration's associate director of medical policy, said in an interview.

" This is a very serious matter. If you get it wrong and over-discourage the use

of these medicines, people could die. "

Dr. Temple was seeking to quell a growing controversy into whether the agency's

warnings on March 22 that antidepressant therapy could lead patients to become

suicidal were sufficient.

" There is concern that we hid data, " said Dr. Temple. " We did not hide data. It

was there for all to see. "

Recent studies have shown that children given antidepressants are more likely to

become suicidal than those given placebos. But the studies have lead to

different interpretations by psychiatrists. The refusal by drug companies to

publish the studies has worsened the confusion. Internal agency documents

obtained by The New York Times show that federal health officials are divided,

too.

Dr. D. Mosholder, an agency epidemiologist, was the man charged with

analyzing 22 studies involving 4,250 children and seven drugs. In a carefully

argued, 33-page memorandum, he concluded that children given antidepressants

were almost twice as likely as those given placebos to become suicidal.

He urged the agency to discourage doctors from prescribing to children all

antidepressants except Prozac. Prozac is the only antidepressant proven

effective in treating depressed children, and its studies showed no link with

suicide, Dr. Mosholder wrote. Dr. Mosholder's conclusions mirrored those made by

British health authorities.

But Dr. Mosholder's supervisors, Drs. Mark Avigan and Anne Trontell, wrote

memorandums disagreeing, according to the documents.

" In particular, we disagree that the data are sufficiently robust to advocate

preferential use " of Prozac in children, Dr. Trontell wrote.

Health officials convened a special advisory committee on Feb. 2 to offer

guidance on how the agency should respond to the studies. As the agency's

principal reviewer, Dr. Mosholder was scheduled to speak. He was removed from

the agenda, Dr. Temple said.

Senator E. Grassley, a Republican from Iowa and chairman of the Senate

Finance Committee, said he was investigating whether the agency inappropriately

suppressed crucial findings. Representative Joe L. Barton, a Republican from

Texas who is chairman of the House Energy and Commerce Committee, said he was

also investigating.

" It would have been very wrong for the F.D.A. to withhold any information it had

about unintended consequences that might result from the use of antidepressants,

especially for children and adolescents, " Mr. Grassley said.

Dr. Temple was unapologetic about the decision.He said that Dr. Mosholder's

underlying data were presented to the committee but that agency officials

explained that Dr. Mosholder had failed to treat with the appropriate skepticism

some reports of suicidal behavior.

The Food and Drug Administration has hired investigators at Columbia University

to examine reports from about 400 of the 4,250 children and determine

independently which should be classified as suicidal.

The controversy had its start when GlaxoKline sought a six-month extension

to its patents on Paxil. To help guide pediatricians' prescribing habits,

federal law grants such extensions when companies test their medicines in

children.

The company's studies in depressed children failed to show any positive effect.

It was a disappointing finding, but patent extensions are granted even when

studies fail. Reviewing the data, Dr. Mosholder noticed in October 2002 that

they showed a disturbing number of problems listed under the category,

" emotional liability. " Suicidal thoughts and self-injurious behavior were among

the things lumped into this category. Dr. Mosholder asked GlaxoKline to

provide more detail about these cases, according to one of the documents.

In May 2003, the company submitted a new report. It showed that children given

Paxil were more likely to become suicidal than those given placebos. In June,

the agency announced that doctors should avoid using Paxil in depressed

children.

Three days later, according to documents and interviews, the agency asked for

similar data from the makers of Prozac, Zoloft, Luvox, Celexa, Wellbutrin,

Effexor, Serzone and Remeron.

Dr. Mosholder found that 108 of the 4,250 children had done something that

merited being called suicidal. He divided the cases into those who were given

drugs and those given placebos and found that children given drugs were almost

twice as likely to become suicidal as those given placebo.

The agency declined to make Dr. Mosholder available for an interview.

Copyright 2004 The New York Times Company | Home | Privacy Policy | Search |

Corrections | Help | Back to Top

[Guest guest]

April 16, 2004

Expert Kept From Speaking at Antidepressant Hearing

By GARDINER HARRIS

op Food and Drug Administration officials admitted yesterday that they barred

the agency's top expert from testifying at a public hearing about his conclusion

that antidepressants cause children to become suicidal because they viewed his

findings as alarmist and premature.

" It would have been entirely inappropriate to present as an F.D.A. conclusion an

analysis of data that were not ripe, " Dr. Temple, the Food and Drug

Administration's associate director of medical policy, said in an interview.

" This is a very serious matter. If you get it wrong and over-discourage the use

of these medicines, people could die. "

Dr. Temple was seeking to quell a growing controversy into whether the agency's

warnings on March 22 that antidepressant therapy could lead patients to become

suicidal were sufficient.

" There is concern that we hid data, " said Dr. Temple. " We did not hide data. It

was there for all to see. "

Recent studies have shown that children given antidepressants are more likely to

become suicidal than those given placebos. But the studies have lead to

different interpretations by psychiatrists. The refusal by drug companies to

publish the studies has worsened the confusion. Internal agency documents

obtained by The New York Times show that federal health officials are divided,

too.

Dr. D. Mosholder, an agency epidemiologist, was the man charged with

analyzing 22 studies involving 4,250 children and seven drugs. In a carefully

argued, 33-page memorandum, he concluded that children given antidepressants

were almost twice as likely as those given placebos to become suicidal.

He urged the agency to discourage doctors from prescribing to children all

antidepressants except Prozac. Prozac is the only antidepressant proven

effective in treating depressed children, and its studies showed no link with

suicide, Dr. Mosholder wrote. Dr. Mosholder's conclusions mirrored those made by

British health authorities.

But Dr. Mosholder's supervisors, Drs. Mark Avigan and Anne Trontell, wrote

memorandums disagreeing, according to the documents.

" In particular, we disagree that the data are sufficiently robust to advocate

preferential use " of Prozac in children, Dr. Trontell wrote.

Health officials convened a special advisory committee on Feb. 2 to offer

guidance on how the agency should respond to the studies. As the agency's

principal reviewer, Dr. Mosholder was scheduled to speak. He was removed from

the agenda, Dr. Temple said.

Senator E. Grassley, a Republican from Iowa and chairman of the Senate

Finance Committee, said he was investigating whether the agency inappropriately

suppressed crucial findings. Representative Joe L. Barton, a Republican from

Texas who is chairman of the House Energy and Commerce Committee, said he was

also investigating.

" It would have been very wrong for the F.D.A. to withhold any information it had

about unintended consequences that might result from the use of antidepressants,

especially for children and adolescents, " Mr. Grassley said.

Dr. Temple was unapologetic about the decision.He said that Dr. Mosholder's

underlying data were presented to the committee but that agency officials

explained that Dr. Mosholder had failed to treat with the appropriate skepticism

some reports of suicidal behavior.

The Food and Drug Administration has hired investigators at Columbia University

to examine reports from about 400 of the 4,250 children and determine

independently which should be classified as suicidal.

The controversy had its start when GlaxoKline sought a six-month extension

to its patents on Paxil. To help guide pediatricians' prescribing habits,

federal law grants such extensions when companies test their medicines in

children.

The company's studies in depressed children failed to show any positive effect.

It was a disappointing finding, but patent extensions are granted even when

studies fail. Reviewing the data, Dr. Mosholder noticed in October 2002 that

they showed a disturbing number of problems listed under the category,

" emotional liability. " Suicidal thoughts and self-injurious behavior were among

the things lumped into this category. Dr. Mosholder asked GlaxoKline to

provide more detail about these cases, according to one of the documents.

In May 2003, the company submitted a new report. It showed that children given

Paxil were more likely to become suicidal than those given placebos. In June,

the agency announced that doctors should avoid using Paxil in depressed

children.

Three days later, according to documents and interviews, the agency asked for

similar data from the makers of Prozac, Zoloft, Luvox, Celexa, Wellbutrin,

Effexor, Serzone and Remeron.

Dr. Mosholder found that 108 of the 4,250 children had done something that

merited being called suicidal. He divided the cases into those who were given

drugs and those given placebos and found that children given drugs were almost

twice as likely to become suicidal as those given placebo.

The agency declined to make Dr. Mosholder available for an interview.

Copyright 2004 The New York Times Company | Home | Privacy Policy | Search |

Corrections | Help | Back to Top

[Guest guest]

April 16, 2004

Expert Kept From Speaking at Antidepressant Hearing

By GARDINER HARRIS

op Food and Drug Administration officials admitted yesterday that they barred

the agency's top expert from testifying at a public hearing about his conclusion

that antidepressants cause children to become suicidal because they viewed his

findings as alarmist and premature.

" It would have been entirely inappropriate to present as an F.D.A. conclusion an

analysis of data that were not ripe, " Dr. Temple, the Food and Drug

Administration's associate director of medical policy, said in an interview.

" This is a very serious matter. If you get it wrong and over-discourage the use

of these medicines, people could die. "

Dr. Temple was seeking to quell a growing controversy into whether the agency's

warnings on March 22 that antidepressant therapy could lead patients to become

suicidal were sufficient.

" There is concern that we hid data, " said Dr. Temple. " We did not hide data. It

was there for all to see. "

Recent studies have shown that children given antidepressants are more likely to

become suicidal than those given placebos. But the studies have lead to

different interpretations by psychiatrists. The refusal by drug companies to

publish the studies has worsened the confusion. Internal agency documents

obtained by The New York Times show that federal health officials are divided,

too.

Dr. D. Mosholder, an agency epidemiologist, was the man charged with

analyzing 22 studies involving 4,250 children and seven drugs. In a carefully

argued, 33-page memorandum, he concluded that children given antidepressants

were almost twice as likely as those given placebos to become suicidal.

He urged the agency to discourage doctors from prescribing to children all

antidepressants except Prozac. Prozac is the only antidepressant proven

effective in treating depressed children, and its studies showed no link with

suicide, Dr. Mosholder wrote. Dr. Mosholder's conclusions mirrored those made by

British health authorities.

But Dr. Mosholder's supervisors, Drs. Mark Avigan and Anne Trontell, wrote

memorandums disagreeing, according to the documents.

" In particular, we disagree that the data are sufficiently robust to advocate

preferential use " of Prozac in children, Dr. Trontell wrote.

Health officials convened a special advisory committee on Feb. 2 to offer

guidance on how the agency should respond to the studies. As the agency's

principal reviewer, Dr. Mosholder was scheduled to speak. He was removed from

the agenda, Dr. Temple said.

Senator E. Grassley, a Republican from Iowa and chairman of the Senate

Finance Committee, said he was investigating whether the agency inappropriately

suppressed crucial findings. Representative Joe L. Barton, a Republican from

Texas who is chairman of the House Energy and Commerce Committee, said he was

also investigating.

" It would have been very wrong for the F.D.A. to withhold any information it had

about unintended consequences that might result from the use of antidepressants,

especially for children and adolescents, " Mr. Grassley said.

Dr. Temple was unapologetic about the decision.He said that Dr. Mosholder's

underlying data were presented to the committee but that agency officials

explained that Dr. Mosholder had failed to treat with the appropriate skepticism

some reports of suicidal behavior.

The Food and Drug Administration has hired investigators at Columbia University

to examine reports from about 400 of the 4,250 children and determine

independently which should be classified as suicidal.

The controversy had its start when GlaxoKline sought a six-month extension

to its patents on Paxil. To help guide pediatricians' prescribing habits,

federal law grants such extensions when companies test their medicines in

children.

The company's studies in depressed children failed to show any positive effect.

It was a disappointing finding, but patent extensions are granted even when

studies fail. Reviewing the data, Dr. Mosholder noticed in October 2002 that

they showed a disturbing number of problems listed under the category,

" emotional liability. " Suicidal thoughts and self-injurious behavior were among

the things lumped into this category. Dr. Mosholder asked GlaxoKline to

provide more detail about these cases, according to one of the documents.

In May 2003, the company submitted a new report. It showed that children given

Paxil were more likely to become suicidal than those given placebos. In June,

the agency announced that doctors should avoid using Paxil in depressed

children.

Three days later, according to documents and interviews, the agency asked for

similar data from the makers of Prozac, Zoloft, Luvox, Celexa, Wellbutrin,

Effexor, Serzone and Remeron.

Dr. Mosholder found that 108 of the 4,250 children had done something that

merited being called suicidal. He divided the cases into those who were given

drugs and those given placebos and found that children given drugs were almost

twice as likely to become suicidal as those given placebo.

The agency declined to make Dr. Mosholder available for an interview.

Copyright 2004 The New York Times Company | Home | Privacy Policy | Search |

Corrections | Help | Back to Top